[Navelbine plus cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 42 cases].
To evaluate the results of combination chemotheray with navelbine (NVB) plus cisplatin (DDP) in the treatment of non-small cell lung cancer (NSCLC). From 1992 through 1996, 42 patients with advanced NSCLC were enrolled in this study. The median age of the patients was 57 years. Adenocarcinoma was the most common type of malignancy. Seventeen patients had stage IIIB disease and 25 had stage IV. Twenty-four patients had no prior chemotherapy and 18 received previous chemotherapy. Partial response was observed in 20 patients with an overall response rate of 47.6%. The response appeared to correlate with dose intensity, as 54.2% response rate was achieved with a dose of NVB > or = 25 mg/m2/wk versus 38.9% response rate with NVB < 25 mg/m2/wk. The median response duration was 3.3 months and the median survival period was 8.5 months. The dose limiting toxicity was neutropenia which was seen in all treated cases (66.6% in grades III and IV). The local venous toxicity was observed in 40.5% of the patients. A high response rate was obtained in advanced NSCLC treated by NVB plus DDP. NVB is a promising antitumor agent with tolerable toxicity.